Factors Predicting Effectiveness of Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma

被引:4
|
作者
Ohkura, Yu [1 ]
Ueno, Masaki [1 ]
Iizuka, Toshiro [2 ]
Haruta, Shusuke [1 ]
Tanaka, Tsuyoshi [1 ]
Udagawa, Harushi [1 ]
机构
[1] Toranomon Gen Hosp, Dept Surg Gastroenterol, Tokyo, Japan
[2] Toranomon Gen Hosp, Gastroenterol, Tokyo, Japan
关键词
ATHEROSCLEROTIC CARDIOVASCULAR-DISEASES; POSITRON-EMISSION-TOMOGRAPHY; SOCIETY JAS GUIDELINES; TUMOR HYPOXIA; CHEMORADIATION THERAPY; MYOCARDIAL-INFARCTION; JAPAN-2012; VERSION; CANCER; CHEMORADIOTHERAPY; RADIOTHERAPY;
D O I
10.1097/MD.0000000000003365
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of the study was to elucidate pretreatment factors that can predict the outcome of neoadjuvant chemoradiotherapy or chemotherapy (NAC(R)T) and help us choose treatment strategies appropriate for individual patients. Few studies have investigated whether clinical data obtainable before the treatment can predict the efficacy of NAC(R) T. Of 1540 patients treated for esophageal squamous cell carcinoma (ESCC) at our department between January 2000 and June 2014, those who underwent surgical resection of cStage II or more advanced ESCC after NAC(R) T (113 NACRT and 146 NACT patients) were enrolled in this study. Information all available before the treatment was analyzed to extract factors that can predict the effectiveness of NAC(R) T. NAC(R) T was considered effective when Grade 2 or greater treatment efficacy was achieved based on the histological grading system. NACRT was effective in 51 (45%) of 113 patients. The analysis of 35 pretreatment factors showed that female sex (hazard ratio [HR] = 3.650; 1.181-11.236), absence of dyslipidemia (HR = 3.284; 1.341-8.041), and histologically poorly differentiated tumor (HR = 2.431; 1.052-5.619) were factors predicting NACRT effectiveness. On the other hand, NACT was effective in 21 (14%) of 146 patients. The analysis of pretreatment factors showed that absence of dyslipidemia (HR = 10.204; 1.302-83.33) and therapy with docetaxel, cisplatin, and 5-fluorouracil (HR = 2.097; 1.027-4.280) were factors predicting NACT effectiveness. The findings of this study investigating factors that could predict the outcome of NAC(R) T suggest that the prevalence of dyslipidemia influences the outcome of NAC(R) T for ESCC.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy
    Hiroshi Okumura
    Yasuto Uchikado
    Tetsuro Setoyama
    Masataka Matsumoto
    Tetsuhiro Owaki
    Sumiya Ishigami
    Shoji Natsugoe
    [J]. Surgery Today, 2014, 44 : 421 - 428
  • [2] Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy
    Okumura, Hiroshi
    Uchikado, Yasuto
    Setoyama, Tetsuro
    Matsumoto, Masataka
    Owaki, Tetsuhiro
    Ishigami, Sumiya
    Natsugoe, Shoji
    [J]. SURGERY TODAY, 2014, 44 (03) : 421 - 428
  • [3] Prognostic factors in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiation therapy
    Okumura, Hiroshi
    Uchikado, Yasuto
    Matsumoto, Masataka
    Owaki, Tetsuhiro
    Kita, Yoshiaki
    Omoto, Itaru
    Sasaki, Ken
    Sakurai, Toshihide
    Setoyama, Tetsuro
    Nabeki, Bunpei
    Matsushita, Daisuke
    Ishigami, Sumiya
    Hiraki, Yoshiyuki
    Nakajo, Masayuki
    Natsugoe, Shoji
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (02) : 329 - 334
  • [4] Prognostic factors in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiation therapy
    Hiroshi Okumura
    Yasuto Uchikado
    Masataka Matsumoto
    Tetsuhiro Owaki
    Yoshiaki Kita
    Itaru Omoto
    Ken Sasaki
    Toshihide Sakurai
    Tetsuro Setoyama
    Bunpei Nabeki
    Daisuke Matsushita
    Sumiya Ishigami
    Yoshiyuki Hiraki
    Masayuki Nakajo
    Shoji Natsugoe
    [J]. International Journal of Clinical Oncology, 2013, 18 : 329 - 334
  • [5] A Transcriptomic Liquid Biopsy Assay for Predicting Resistance to Neoadjuvant Therapy in Esophageal Squamous Cell Carcinoma
    Okuno, Keisuke
    Tokunaga, Masanori
    Kinugasa, Yusuke
    Baba, Hideo
    Kodera, Yasuhiro
    Goel, Ajay
    [J]. ANNALS OF SURGERY, 2022, 276 (01) : 101 - 110
  • [6] The application of neoadjuvant therapy in thoracic esophageal squamous cell carcinoma
    Hao, Yanmei
    Zhu, Chaomang
    Tao, Suyu
    Li, Duojie
    Wei, Nannan
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (05): : 6275 - 6282
  • [7] NEOADJUVANT THERAPY FOR SQUAMOUS-CELL ESOPHAGEAL-CARCINOMA
    FINK, U
    STEIN, HJ
    BOCHTLER, H
    RODER, JD
    WILKE, HJ
    SIEWERT, JR
    [J]. ANNALS OF ONCOLOGY, 1994, 5 : S17 - S26
  • [8] Neoadjuvant treatment for esophageal squamous cell carcinoma
    Yoshifumi Baba
    Masayuki Watanabe
    Naoya Yoshida
    Hideo Baba
    [J]. World Journal of Gastrointestinal Oncology, 2014, (05) : 121 - 128
  • [9] Neoadjuvant treatment for esophageal squamous cell carcinoma
    Baba, Yoshifumi
    Watanabe, Masayuki
    Yoshida, Naoya
    Baba, Hideo
    [J]. WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2014, 6 (05) : 121 - 128
  • [10] A MULTI-OMIC LIQUID BIOPSY ASSAY FOR PREDICTING THE RESISTANCE TO NEOADJUVANT THERAPY IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA
    Okuno, Keisuke
    Tokunaga, Masanori
    Kinugasa, Yusuke
    Baba, Hideo
    Kodera, Yasuhiro
    Goel, Ajay
    [J]. GASTROENTEROLOGY, 2022, 162 (07) : S296 - S296